Novavax Q3 Revenue Tops Estimates at $70.45M, Q4 Growth Seen at 5.9%
Novavax reported Q3 revenue of $70.45 million, down 16.6% year-on-year, topping sales forecasts but missing EPS, and is forecast to post 5.9% revenue growth in Q4 after a 69.7% plunge last year. Analysts maintained estimates last month while shares dropped 3.8% versus a 1.9% peer decline, with a $13 target.
1. Q3 Financial Overview
Novavax posted Q3 revenue of $70.45 million, marking a 16.6% decline year-on-year. While revenue exceeded analyst targets, the company fell short on earnings per share, reflecting ongoing margin pressure.
2. Q4 Revenue Outlook
Analysts project Novavax will reverse last year’s 69.7% Q4 revenue drop with 5.9% year-on-year growth. This forecast assumes improving vaccine demand and product rollout in key markets.
3. Analyst Estimate Trends
Coverage analysts have largely maintained their revenue and EPS estimates over the past month. Novavax has, however, missed Wall Street’s revenue targets multiple times in the past two years, underscoring forecast risks.
4. Peer Comparison and Stock Performance
Biogen’s Q4 revenue fell 7.1% but beat estimates, while Halozyme posted 51.6% growth, highlighting mixed sector trends. Novavax shares have slid 3.8% this month versus a 1.9% average drop among therapeutics peers.